Harbor Capital Advisors Inc. boosted its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 140.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 422,421 shares of the technology company's stock after purchasing an additional 246,400 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.36% of Evolent Health worth $11,946,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of EVH. US Bancorp DE lifted its position in shares of Evolent Health by 180.3% during the 3rd quarter. US Bancorp DE now owns 6,579 shares of the technology company's stock valued at $186,000 after buying an additional 4,232 shares in the last quarter. Values First Advisors Inc. lifted its holdings in Evolent Health by 21.0% during the third quarter. Values First Advisors Inc. now owns 32,129 shares of the technology company's stock valued at $909,000 after purchasing an additional 5,583 shares in the last quarter. Moody Aldrich Partners LLC acquired a new stake in shares of Evolent Health in the third quarter valued at about $1,421,000. Friedenthal Financial purchased a new stake in shares of Evolent Health during the third quarter worth about $723,000. Finally, Creative Planning increased its stake in Evolent Health by 139.1% during the 3rd quarter. Creative Planning now owns 43,262 shares of the technology company's stock worth $1,223,000 after buying an additional 25,171 shares in the last quarter.
Evolent Health Stock Up 0.5 %
Shares of EVH traded up $0.11 during mid-day trading on Friday, hitting $23.46. 1,009,619 shares of the company's stock were exchanged, compared to its average volume of 1,569,861. The stock's 50-day moving average is $27.80 and its 200-day moving average is $25.10. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.08 and a current ratio of 1.08. Evolent Health, Inc. has a fifty-two week low of $17.98 and a fifty-two week high of $35.00. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -24.96 and a beta of 1.58.
Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, August 8th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.09. The company had revenue of $647.10 million for the quarter, compared to analyst estimates of $636.46 million. Evolent Health had a negative net margin of 3.16% and a positive return on equity of 8.47%. The firm's quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.06 EPS. On average, sell-side analysts anticipate that Evolent Health, Inc. will post 0.84 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, President Daniel Joseph Mccarthy sold 23,693 shares of Evolent Health stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total value of $731,876.77. Following the completion of the transaction, the president now owns 198,809 shares in the company, valued at approximately $6,141,210.01. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, President Daniel Joseph Mccarthy sold 23,693 shares of the firm's stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.89, for a total value of $731,876.77. Following the sale, the president now directly owns 198,809 shares in the company, valued at approximately $6,141,210.01. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Seth Blackley sold 187,904 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $5,637,120.00. Following the completion of the transaction, the chief executive officer now directly owns 411,924 shares in the company, valued at $12,357,720. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 307,291 shares of company stock worth $9,290,385 in the last quarter. 1.60% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. Citigroup dropped their target price on shares of Evolent Health from $35.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday, October 29th. Royal Bank of Canada restated an "outperform" rating and issued a $42.00 target price on shares of Evolent Health in a report on Tuesday, October 8th. KeyCorp assumed coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an "overweight" rating and a $35.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on shares of Evolent Health from $36.00 to $45.00 and gave the company an "overweight" rating in a report on Monday, August 19th. Finally, Truist Financial restated a "buy" rating and set a $33.00 price target on shares of Evolent Health in a report on Tuesday, August 27th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $38.60.
Read Our Latest Stock Analysis on EVH
About Evolent Health
(
Free Report)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
See Also
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
